reSee.it - Related Video Feed

Video Saved From X

reSee.it Video Transcript AI Summary

Coronavirus, as a pathogen model, was identified in 1965 and seen as modifiable for various purposes. In 1966, it was used in a transatlantic biological experiment. By 1967, human trials began, inoculating people with modified versions. The common cold was turned into a chimera in the 1970s. By 1990, coronavirus was an industrial problem for dog and pig breeders, leading to Pfizer's first spike protein vaccine patent. However, from 1990 to 2018, research indicated coronavirus mutated too quickly for vaccines to be effective. In 2002, the University of North Carolina Chapel Hill patented an "infectious replication defective" clone of coronavirus, funded by NIAID's Anthony Fauci, preceding SARS 1.0. SARS is engineered, not naturally occurring like the common cold.

Video Saved From X

reSee.it Video Transcript AI Summary

Scientists are investigating claims that COVID-19 was manipulated in a lab after a tiny DNA fragment matching a sequence patented by Moderna was found in the virus. The possibility of an accidental lab escape is being considered, as human error is always a factor. The Wuhan lab in China may have been conducting research on virus enhancement or gene modification, leading to an infection that spread to others. The scientists are currently analyzing the data to determine the validity of these claims. It will take time to thoroughly examine the genetic evidence.

Video Saved From X

reSee.it Video Transcript AI Summary

We have been studying epidemics for about forty years, particularly looking at the issue of legislation. Working with animals, such as chickens with bronchitis caused by coronavirus, has been somewhat simpler. Despite thirty years of trying various vaccines, we have not been able to control it effectively. So, why is it that we suddenly find a solution for humans when we have struggled to find one for the flu? How can we achieve this?

Video Saved From X

reSee.it Video Transcript AI Summary

We need to be proactive in searching for emerging diseases before they become a global threat. Peter Daszak, who collaborated with the Wuhan Institute of Virology, discovered 50 previously unknown Coronaviruses in bats. These Coronaviruses have the potential to jump from wildlife to humans. Our organization works with labs worldwide, subcontracting the work and ensuring we have a country program officer in each location to manage our projects.

Video Saved From X

reSee.it Video Transcript AI Summary

In 1965, coronavirus was identified as a pathogen that could be modified for various purposes. The first human manipulation experiment took place in 1966, followed by transatlantic data sharing in 1967. In the 1970s, coronavirus was modified in animals like pigs and dogs. By 1990, it was discovered that coronavirus caused gastrointestinal issues in dogs and pigs, leading to Pfizer filing the first spike protein vaccine patent. The spike protein was not a new problem, as it was known since 1990. Vaccines for coronavirus have been ineffective due to its ability to mutate quickly, as stated in numerous independent scientific publications. In 2002, the University of North Carolina Chapel Hill patented an infectious replication defective clone of coronavirus, funded by Anthony Fauci. This suggests that SARS was engineered and not a naturally occurring phenomenon.

Video Saved From X

reSee.it Video Transcript AI Summary

We isolated coronaviruses from animals in the past to understand their threat to other species by culturing them on different cell types. This process, known as gain of function, involves enriching mutants that can infect new species. The speaker emphasizes that mass vaccination in humans is a significant gain of function experiment, leading to virus evolution. This real-world experiment involves constant virus changes due to human-to-human transmission under vaccine pressure.

Video Saved From X

reSee.it Video Transcript AI Summary

Concerning research from China was published last week. Researchers took a virus from pangolins and cultured it in a lab. They then infected mice with this virus, which killed all of them through brain infection. These mice were transgenic, meaning they had human ACE receptor genes. The virus, a coronavirus from pangolins, killed all the infected mice. This kind of experimentation is dangerous and should be banned immediately.

Video Saved From X

reSee.it Video Transcript AI Summary

The speaker discusses the global wildlife trade and its connection to the emergence of new diseases. They focus on SARS and how it originated from a wildlife market. Through surveillance of bats in Southern China, they have discovered over 100 new SARS-related coronaviruses that pose a threat to humans. Some of these coronaviruses can infect human cells and cause SARS-like disease. The speaker emphasizes the need for continued surveillance and understanding of these spillover events, as any one of them could potentially lead to a pandemic. They also mention the challenges in developing vaccines and antivirals for these diverse coronaviruses.

Video Saved From X

reSee.it Video Transcript AI Summary

Coronavirus was isolated in 1965 and quickly identified as a pathogen for experimentation. In 1966, the first COV model was used in human manipulation experiments. By 1990, Pfizer patented a spike protein vaccine for coronavirus. Research showed vaccines were ineffective due to the virus mutating rapidly. In 2002, the University of North Carolina patented an infectious replication defective clone of coronavirus, funded by Anthony Fauci. This work preceded SARS 1.0 by a year, suggesting engineered origins.

Video Saved From X

reSee.it Video Transcript AI Summary

Coronavirus was isolated in 1965 as one of the first infectious replicatable viral models, associated with the common cold. In 1966, the very first COV coronavirus model was used as a transatlantic biological experiment in human manipulation. In 1967, the first human trials on inoculating people with modified coronavirus were conducted. Between 1975 and 1977, we started modifying coronavirus by putting it into different animals, pigs and dogs. By 1990, Pfizer's first spike protein vaccine patent for coronavirus was filed. From 1990 to 02/2018, every publication on coronavirus vaccines concluded that coronavirus escapes the vaccine impulse because it mutates too quickly. In 02/2002, UNC Chapel Hill patented ‘an infectious replication defective clone of coronavirus’ funded by NIAID's Anthony Fauci from 1999 to 02/2002. That work allegedly preceded SARS-1; SARS is the research developed by humans weaponizing a life system model to attack human beings, patented in 02/2002.

Video Saved From X

reSee.it Video Transcript AI Summary

The NIH is developing a universal vaccine that addresses the entire phylum of viruses. This vaccine mimics natural immunity and is effective against any kind of mutation. It doesn't drive the virus to mutate. The researchers believe it could be effective not only against coronaviruses but also against influenza. The vaccine is described as much safer and much more effective. The exchange then notes that Mark, did you take your question again? and Mark is prompted to ask his question.

Video Saved From X

reSee.it Video Transcript AI Summary

We are working on developing new vaccines like TB and HIV using mRNA technology to make them high quality and low cost. Current COVID vaccines are not perfect, so we are working on new versions with longer-lasting protection for diseases like measles and tuberculosis. The mRNA technology also shows promise for cancer vaccines and rapid adaptation to future pandemics. We are even exploring using this technology for animal vaccines.

Video Saved From X

reSee.it Video Transcript AI Summary

Chinese researchers have created a super virus by combining a protein from bats with the SARS virus found in mice. This virus could potentially infect humans, although it is currently only being studied in laboratories. The debate over the risks of this research is not new, with some scientists arguing that the benefits outweigh the potential dangers. However, others are concerned about the possibility of the virus directly infecting humans without an intermediate species. The US government had previously suspended funding for research aiming to make viruses more contagious, but this did not stop the Chinese research on SARS. Some experts believe the chances of the virus spreading to humans are minimal compared to the potential benefits, while others disagree.

Video Saved From X

reSee.it Video Transcript AI Summary

NIH is pursuing a universal vaccine designed to cover the entire range of viruses, aiming to mimic natural immunity. The developers claim it would be effective against any mutation and would not drive the virus to mutate. They expect the approach could work not only for coronaviruses but also for flu, offering broad protection. They describe the vaccine as safer and more effective than current options. The dialogue centers on ongoing questions as the project advances, emphasizing a shift toward a single, universal solution that could, if successful, provide cross-viral protection and reduce the need for virus-specific vaccines. The statements focus on safety, efficacy, and cross-coverage across coronaviruses and influenza.

Video Saved From X

reSee.it Video Transcript AI Summary

In 2015, the National Library of Medicine published a study by 15 virologists and medical experts warning that SARS-like bat coronaviruses pose a potential threat to humans. The scientists, with decades of experience in studying coronaviruses, examined how SARS and MERS transmitted among humans. They modified a strain of coronavirus from Chinese horseshoe bats using gain of function technology and injected it into mice spinal cords. This study not only highlights the dangers of coronaviruses in bats but also demonstrates efforts to amplify the virus's contagion ability to better understand and prepare for future outbreaks.

Video Saved From X

reSee.it Video Transcript AI Summary

Evolutionary virologists analyzed viral sequences from the current outbreak and in bats. They determined that the mutations required for the virus to jump from an animal to a human are entirely consistent with its evolutionary path. A paper detailing this research will be made available, although the authors are not currently named.

Video Saved From X

reSee.it Video Transcript AI Summary

In South America and Southeast Asia, there are many bat species carrying unknown viruses, making them potential sources of future pandemics. The USAID EPT predict program and NIAID funding allowed researchers to predict and prepare for emergencies like the SARS outbreak. They discovered that SARS-like viruses originate from bats in China, with some being almost identical to SARS. Surveillance of bat hunters and nearby residents revealed the potential for spillover into human populations. While there are no vaccines or antivirals for these diverse coronaviruses, scientists can manipulate them in the lab by studying their spike proteins. This knowledge can aid in the development of better vaccines and therapeutics. However, predicting and anticipating pandemics does not guarantee prevention.

Video Saved From X

reSee.it Video Transcript AI Summary

We are working on developing new vaccines for diseases like TB, HIV using mRNA technology. The goal is to create high-quality, low-cost vaccines that can be used for various illnesses. Current COVID vaccines have limitations, so we are working on next-generation vaccines with longer-lasting protection. mRNA technology also shows promise for cancer vaccines and potential future pandemics. Additionally, we are exploring using this technology for animal vaccines.

Video Saved From X

reSee.it Video Transcript AI Summary

COVID-19 is believed to be a man-made pandemic, specifically the SARS-CoV-2 virus created in the Wuhan Institute of Virology through a US-Chinese collaboration. The virus was engineered with the goal of developing a vaccine.

Video Saved From X

reSee.it Video Transcript AI Summary

This video discusses the coronavirus and the ongoing research programs to develop vaccines against similar viruses that have previously crossed over from animals to humans. The question is raised whether these viruses can be modified or adapted to combat the current virus. This research is being conducted globally, including in China.

Video Saved From X

reSee.it Video Transcript AI Summary

Researchers have discovered various coronaviruses in bats, including ones similar to SARS. They focused on the spike protein, which attaches to cells, and conducted experiments in China. By inserting spike proteins from these viruses into pseudoparticles, they tested their ability to bind to human cells. This process allowed them to understand the potential pathogenicity of the virus in humans.

Video Saved From X

reSee.it Video Transcript AI Summary

NIH funded research at Wuhan Institute of Virology through ECHO Health, including gain of function research. This type of research is common in labs nationwide and is not regulated because it is deemed harmless.

Video Saved From X

reSee.it Video Transcript AI Summary

We focus on viral families that have transmitted from animals to humans. When we find a virus that resembles a known dangerous pathogen, like SARS, we examine its spike protein, which attaches to cells. Chinese researchers create pseudo particles with these spike proteins to test if they bind to human cells. This process helps us identify viruses that could potentially be harmful to humans. By narrowing down the field and reducing costs, we end up with a small number of viruses that appear to be dangerous. We then investigate if people living in the same region as the animals carrying these viruses have developed antibodies.

Video Saved From X

reSee.it Video Transcript AI Summary

New vaccines for tuberculosis, malaria, HIV, and COVID-19 are being developed. These vaccines aim to have longer-lasting effects and wider coverage. In addition, instead of using needles, a patch will be used for administration. The COVID-19 pandemic has brought attention to the fact that we have not invested enough in these innovative advancements.

The Peter Attia Drive Podcast

#117 – Stanley Perlman, M.D., Ph.D.: Insights from a coronavirus expert on COVID-19

Guests: Stanley Perlman

reSee.it Podcast Summary

In this episode of The Drive podcast, host Peter Attia speaks with Dr. Stanley Perlman, a professor of microbiology and immunology at the University of Iowa, who has studied coronaviruses for nearly four decades. They discuss the evolution and impact of coronaviruses, including SARS-CoV-1, MERS, and the current SARS-CoV-2, emphasizing the importance of understanding immune responses and the potential for future pandemics. Dr. Perlman explains that coronaviruses are categorized based on their structure and replication strategies. He notes that while some coronaviruses cause mild illnesses like the common cold, others, such as SARS and MERS, can lead to severe respiratory diseases. The discussion highlights the unique characteristics of coronaviruses, including their large genetic material and ability to infect multiple species, particularly bats, which are believed to be the original hosts of many coronaviruses. The conversation shifts to the immune response to these viruses, with Dr. Perlman emphasizing that immunity to coronaviruses can wane over time, complicating efforts to achieve herd immunity. They explore the implications of this for vaccination strategies, suggesting that vaccines may need to be administered annually, similar to influenza vaccines. Dr. Perlman also discusses the challenges of studying the durability of immune responses, particularly in the context of SARS-CoV-2. He stresses the need for ongoing research to understand how long immunity lasts and how it affects transmissibility within the community. The episode concludes with reflections on the lessons learned from past coronavirus outbreaks and the importance of preparedness for future viral threats. Overall, the discussion provides valuable insights into the complexities of coronaviruses, the immune system's response, and the ongoing challenges posed by SARS-CoV-2.